Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs
Top Cited Papers
- 28 April 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (2), 191-200
- https://doi.org/10.1002/cpt.1830
Abstract
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are among the most commonly used analgesics due to their lack of addictive potential. However, NSAIDs have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. CYP2C9 polymorphisms influence metabolism and clearance of several drugs in this class, thereby affecting drug exposure and potentially safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for NSAIDs based on CYP2C9 genotype (updates at www.cpicpgx.org).Keywords
Funding Information
- National Institutes of Health (R24GM115264, U24HG010135, R24GM61374, U24HG010615)
This publication has 41 references indexed in Scilit:
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trialsThe Lancet, 2013
- Effects of the CYP2C9*1/*13 Genotype on the Pharmacokinetics of LornoxicamBasic & Clinical Pharmacology & Toxicology, 2011
- Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for useBritish Journal of Sports Medicine, 2009
- Global variation in CYP2C8–CYP2C9 functional haplotypesThe Pharmacogenomics Journal, 2009
- The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial InfarctionPLOS ONE, 2007
- Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsGut, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJCI Insight, 2005
- Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complicationHeart, 2004
- Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugsThe American Journal of Medicine, 2001
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998